Flibanserin recommended for approval by the FDA Advisory Committee Panel

Dear ISSWSH members,
It is with great excitement that I share the announcement that flibanserin, a drug for hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was recommended for approval by the FDA Advisory Committee Panel on June 4, 2015.

This event opens the door for the first treatment for women suffering from HSDD, but more importantly sends the message that the FDA is now willing to entertain new drug applications from other companies. We are optimistic that this occurrence will instigate more research and eventually other therapeutic options. We also offer deep gratitude to many of our members who played a key role in this decision by voting as members of the FDA Advisory Panel, speaking as presenters on behalf of the sponsor, providing testimony during the Open Public Hearing, and caring for patients who also spoke at the Hearing.  

As a multidisciplinary, scientific organization dedicated to research, clinical practice, and education, we are poised to develop and disseminate clinical practice guidelines regarding screening, diagnosis, and management strategies. Through our robust infrastructure of educational programs, we will ensure appropriate, safe, and selective treatment of HSDD with flibanserin when final approval comes.

Most sincerely,
Sharon J. Parish, MD, IF
ISSWSH President, 2014-2016

Save the Date

ISSWSH Fall Course 2020
Cancelled

ISSWSH Virtual Course 2020
November 6, 13, & 20, 2020  
Virtual
Stay tuned for updates

ISSWSH Annual Meeting 2021
March 4-7, 2021   210 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

Well if this isn't another good reason to have sex - delay menopause. https://t.co/cgeHZMfyzo ISSWSH
It's good to be alive now! 250 years ago, over one-fifth of Londoners had contracted syphilis by their 35th birthda… https://t.co/k0gRN0ZR0B ISSWSH
Wondering how to get your grove on? How to initiate sex https://t.co/X41FW5AlPS ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram